Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 83/100, backed by robust profitability and solvency.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street sentiment is generally neutral. This is paired with healthy capital returns, anchored by a strong, well-covered dividend yield.
NRIM exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins. This is paired with a moderately leveraged but stable balance sheet.
The company maintains stable top-line performance paired with highly explosive earnings growth (29.6% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 35.5% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $62.3M | +23.8% | — | — | +8.8% | |
| EBITDA | $18.2M | — | +28.7% | — | — | |
| Net Income | $12.4M | +74.8% | +28.1% | — | +13.8% | |
| EPS (Diluted) | $0.55 | +72.9% | +29.6% | +17.6% | +16.2% | |
| Free Cash Flow | $32.3M | +1532.2% | +21.7% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 81.4% | 79.5% | 86.7% | 91.0% |
| Operating Margin | 35.5% | 26.5% | 28.6% | 26.8% |
| Net Margin | 26.6% | 20.5% | 22.4% | 20.3% |
| FCF Margin | 55.2% | 23.7% | 41.3% | 22.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.53 | $0.61 | +15.1% | ||
| Q1'26 | — | $0.55 | — | ||
| Q1'26 | $0.64 | $0.54 | -15.6% | ||
| Q4'25 | $0.64 | $0.72 | +13.4% | ||
| Q3'25 | $0.57 | $0.52 | -8.5% | ||
| Q2'25 | $0.42 | $0.60 | +43.3% | ||
| Q1'25 | — | $0.49 | — | ||
| Q1'25 | $0.43 | $0.49 | +14.0% |
Total return is +18.3% (1Y), lagging the benchmark by -6.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -5.0% | -14.3% | — |
| 1Y | +18.3% | -6.7% | +2.9% |
| 3YCAGR | +38.7% | +18.8% | +18.5% |
| 5YCAGR | +21.8% | +7.4% | +26.9% |
| 10YCAGR | +16.4% | +3.0% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Northrim BanCorp, Inc. (NRIM) valuation, health, and returns.
Based on peer relative multiples, Northrim BanCorp, Inc. appears Slightly cheap versus peers compared to industry peers.
Northrim BanCorp, Inc. has multiple valuation anchors: Peer Relative Fair Value: $28.05. A convergence of these signals offers higher conviction.
Northrim BanCorp, Inc. displays excellent financial health with a composite quality score of 83/100, supported by a Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 17.7%.
Northrim BanCorp, Inc. pays a 2.6% dividend yield, covered by a 23% payout ratio with 16 years of growth, supplemented by a 0.0% buyback yield.
Northrim BanCorp, Inc.'s current growth trajectory is Decelerating. The company achieved +23.8% 1Y revenue growth and +72.9% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Buy based on 1 analysts, beating EPS expectations in 67% of recent quarters with a 1-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Northrim BanCorp, Inc. include: -25.4% 1-year max drawdown. Volatility risk is characterized by a beta of 0.88x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.